ERBB2 and neoplasm: Regarding the tumor subtype according to the immunohistochemical findings, the patientswere distributed as follows: 151 patients had luminal A (ER+/PR+ Ki67<15%); 111,luminal B (ER+/PR+ Ki67 ≥15%); 63 cases, hybrid luminal (ER+/PR+, HER2+++/ positiveFish); 20 individuals, HER2 subtype (ER-/PR-, HER2+++/ positive Fish) and 19 patientstriple negative (ER-/PR-, HER2 0, +, ++/Fish negativo) (Table 2).